瑞普生物荣获“中国上市公司新质生产力50强”

Company Overview - The company, Ruipu Biology, is the first A-share listed company in China focusing on the veterinary medicine field [1] - It adheres to the corporate values of "customer-centric,奋斗者为本,敢为人先,使命必达" [1] - The company focuses on cutting-edge developments in biopharmaceuticals such as genetic engineering vaccines, suspension culture processes, new crystal drugs, and AI drug research [1] - It provides comprehensive disease prevention and health solutions for economic and companion animals throughout their life cycles [1] Business Operations - Ruipu Biology has over 20 subsidiary companies spread across 8 provinces and cities including Tianjin, Hubei, and Hunan [1] - The company operates 11 production bases that have passed the new version of veterinary drug GMP acceptance and 1 large-scale feed additive production base [1] - It offers more than 500 animal products for livestock, poultry, and pets [1] - The company is an integrated animal health product manufacturer and service provider, covering biological products, drug raw materials, drug preparations, and feed additives [1] Industry Recognition - Ruipu Biology was recognized in the "China Listed Companies New Quality Productivity 50强" list, reflecting its strong development momentum and market recognition of its new quality productivity [1] - New quality productivity represents new technologies, value creation, adaptation to new industries, and reshaping of new momentum [1] Future Outlook - The company aims to place technological innovation at the core of its development, continuously deepen technological innovation and product iteration, and accelerate its growth [2] - Ruipu Biology aspires to become a leading enterprise in the global animal health industry, contributing to the prosperity of China's animal husbandry, animal health, and human well-being [2]